Last reviewed · How we verify

Placebo capsule (Vitamin K1)

University of Sydney · Phase 3 active Small molecule

Placebo capsule (Vitamin K1) is a Vitamin/Nutritional supplement Small molecule drug developed by University of Sydney. It is currently in Phase 3 development for Placebo control in Phase 3 clinical trial (specific indication unknown). Also known as: Matching placebo capsule.

Vitamin K1 acts as a cofactor for gamma-glutamyl carboxylase, enabling the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and other regulatory proteins.

Vitamin K1 acts as a cofactor for gamma-glutamyl carboxylase, enabling the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and other regulatory proteins. Used for Placebo control in Phase 3 clinical trial (specific indication unknown).

At a glance

Generic namePlacebo capsule (Vitamin K1)
Also known asMatching placebo capsule
SponsorUniversity of Sydney
Drug classVitamin/Nutritional supplement
TargetGamma-glutamyl carboxylase (GGCX)
ModalitySmall molecule
Therapeutic areaHematology/Coagulation
PhasePhase 3

Mechanism of action

Vitamin K1 (phylloquinone) is an essential cofactor required for the post-translational carboxylation of glutamic acid residues in vitamin K-dependent proteins. This carboxylation is critical for the activation of coagulation factors II, VII, IX, and X, as well as anticoagulant proteins C and S. In this Phase 3 trial context, the placebo capsule containing Vitamin K1 serves as the control arm, providing baseline nutritional vitamin K supplementation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo capsule (Vitamin K1)

What is Placebo capsule (Vitamin K1)?

Placebo capsule (Vitamin K1) is a Vitamin/Nutritional supplement drug developed by University of Sydney, indicated for Placebo control in Phase 3 clinical trial (specific indication unknown).

How does Placebo capsule (Vitamin K1) work?

Vitamin K1 acts as a cofactor for gamma-glutamyl carboxylase, enabling the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and other regulatory proteins.

What is Placebo capsule (Vitamin K1) used for?

Placebo capsule (Vitamin K1) is indicated for Placebo control in Phase 3 clinical trial (specific indication unknown).

Who makes Placebo capsule (Vitamin K1)?

Placebo capsule (Vitamin K1) is developed by University of Sydney (see full University of Sydney pipeline at /company/university-of-sydney).

Is Placebo capsule (Vitamin K1) also known as anything else?

Placebo capsule (Vitamin K1) is also known as Matching placebo capsule.

What drug class is Placebo capsule (Vitamin K1) in?

Placebo capsule (Vitamin K1) belongs to the Vitamin/Nutritional supplement class. See all Vitamin/Nutritional supplement drugs at /class/vitamin-nutritional-supplement.

What development phase is Placebo capsule (Vitamin K1) in?

Placebo capsule (Vitamin K1) is in Phase 3.

What are the side effects of Placebo capsule (Vitamin K1)?

Common side effects of Placebo capsule (Vitamin K1) include Adverse events unlikely at nutritional doses.

What does Placebo capsule (Vitamin K1) target?

Placebo capsule (Vitamin K1) targets Gamma-glutamyl carboxylase (GGCX) and is a Vitamin/Nutritional supplement.

Related